SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)

November 29, 2018

NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/halo.

The investigation concerns whether Halozyme and certain of its officers and/or directors have violated federal securities laws.

On November 26, 2018, Halozyme issued a press release announcing “that prior to data analysis, the [U.S. Food and Drug Administration] has agreed to Halozyme’s request to change the primary endpoint of the HALO-301 study to the single primary endpoint of overall survival (OS). As a result, the previously planned interim analysis will not be conducted.” Following this announcement, Halozyme’s stock price fell $1.24 per share, or 7.42%, to close at $15.47 per share on November 27, 2018.

If you are aware of any facts relating to this investigation, or purchased Halozyme shares, you can assist this investigation by visiting the firm’s site: bgandg.com/halo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

Update hourly